chevron_leftBack
As of 25 June 2026, Anya Biopharm Inc. has a market cap of $47.13M USD, ranking #30956 globally and #1868 in Taiwan.
It ranks #2796 in the Healthcare sector, and #979 in the Drug Manufacturers - General industry.
Key Stats
Market Cap
$47.13MUSD
1.49B TWD
Enterprise Value
$35.42MUSD
1.13B TWD
Revenue (TTM)
$513.77KUSD
16.27M TWD
EBITDA (TTM)
-$1.79MUSD
-56.83M TWD
Net Income (TTM)
-$2.02MUSD
-64.02M TWD
PS Ratio
91.7
PB Ratio
3.7
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Gerui Shi
open_in_new
Founded
2016
Website
anyabiopharm.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -1.3% | -7% | -8.2% | -23% | -36% | 0.7% |
News
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
7776
奧孟亞股份有限公司
ISIN: TW0007776007
Shares Out.:
Shares Outstanding:
49.102M1
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
30.40 TWD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Anya Biopharm Inc.
Anya Biopharm Inc., a pharmaceutical company, research and development of new biotech drugs, focusing on oral peptides and converting injectable drugs into oral formulations in Taiwan, the rest of Asia, and Europe. The company is also developing ANY002 and ANY004, oral GLP1 products; ANY003, a tnfα inhibitor; and ANY005. In addition, it engages in the research, development, and testing business. Anya Biopharm Inc. was founded in 2016 and is based in Taipei, Taiwan.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
TWSE: 6446
|
$7.75B
16K%
245.34B TWD
|
48.6
|
|
TWSE: 1795
|
$1.83B
4K%
57.95B TWD
|
12.2
|
|
TPEX: 4123
|
$919.32M
2K%
29.11B TWD
|
3.4
|
|
TPEX: 6535
|
$803.85M
2K%
25.46B TWD
|
-
|
|
TPEX: 4743
|
$783.82M
2K%
24.82B TWD
|
-
|
|
TPEX: 4105
|
$580.21M
1K%
18.38B TWD
|
11.8
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NYSE: LLY
|
$761.68B
2M%
|
38.1
|
|
NYSE: JNJ
|
$547.28B
1M%
|
26.4
|
|
NYSE: ABBV
|
$360.63B
765K%
|
97.4
|
|
SIX: RO
|
$316.37B
671K%
256.25B CHF
|
19.9
|
|
LSE: AZN
|
$284.33B
603K%
215.59B GBP
|
27.6
|
|
NYSE: MRK
|
$274.03B
581K%
|
15.1
|
chevron_leftBack